SIAH2抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P12165(SIAH2 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P12165(SIAH2 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The SIAH2 (Seven In Absentia Homolog 2) antibody is a crucial tool for studying the SIAH2 protein, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. SIAH2 plays a key role in regulating cellular processes such as apoptosis, hypoxia response, and tumorigenesis by targeting substrates like PHD3. AKT, and β-catenin for proteasomal degradation. Its activity is often upregulated in cancers, making it a focus in oncology research.

SIAH2 antibodies are designed to detect and quantify endogenous SIAH2 protein levels in various experimental settings, including Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. These antibodies are typically produced in hosts like rabbits or mice, with monoclonal variants offering high specificity and polyclonal versions providing broader epitope recognition. Validation parameters, such as reactivity across species (human, mouse, rat) and application-specific optimization, ensure reliability in diverse research models.

Researchers use SIAH2 antibodies to explore its role in cancer progression, metabolic reprogramming, and therapeutic resistance. Dysregulation of SIAH2 is linked to tumor growth, metastasis, and poor prognosis, making it a potential biomarker or therapeutic target. Recent studies also investigate its interplay with hypoxia-inducible factors (HIFs) and oncogenic signaling pathways. As interest in ubiquitin-mediated regulation grows, SIAH2 antibodies remain essential for unraveling its multifaceted biological and pathological functions.